Regional Regulations

Why location matters

The same peptide vial can be a sales violation in one country and a possession offense in the next. Some regulators treat an unapproved peptide as an unapproved drug and pursue the sellers. Others classify it as a prescription medicine, which can make owning it without a prescription unlawful too.

One point holds everywhere we checked: a "research use only" label doesn't make selling a peptide for human use legal. The FDA says so in its 2026 warning letters. Australia's TGA and New Zealand's Medsafe said it in 2026 alerts. Health Canada says the same, and Singapore's Health Sciences Authority describes such labels as an attempt to get around regulatory controls.

This page covers drug law: who may sell or import a peptide, and whether owning one is an offense. Anti-doping rules are a separate system, covered on our page on competitive sports rules for peptides.

Regions at a glance

As of October 2026:

United States

The FDA judges whether a product is a drug by its intended use, and the label is only one piece of evidence. In warning letters dated August 24, 2026, it told several sellers that their websites showed the products were meant for people despite "research use only" disclaimers. The letter to Peak Performance Peptides quoted product copy as mild as "studied for effects on glycemic control." It also cited the bacteriostatic water sold alongside the vials as evidence they were meant to be injected. Retatrutide and tesamorelin were among the five peptides it named as unapproved new drugs.

Compounding is the other legal route. A pharmacy may compound from bulk powder only if the substance has a USP monograph, is part of an approved drug, or is on FDA's 503A bulks list. In April 2026, FDA removed 12 peptides from Category 2 (nominated substances with significant safety concerns) after their nominators withdrew. BPC-157 and TB-500 were among them, but removal didn't make them legal to compound. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted on seven of them, although FDA staff had recommended against all seven:

• Recommended for the bulks list: BPC-157, KPV and TB-500 (each 8-6-1), MOTS-c (7-5-2), Semax (8-5-1) and epitalon (7-4-1)
• Recommended against: DSIP (6-7-1)

A committee vote is advice; FDA still has to complete rulemaking before anything joins the list. A pharmacy law firm reported in August that nothing had followed, and as of October 2026 we found no proposed rule. A second meeting on five more peptides is planned before the end of February 2027.

Enforcement has reached prison time. On July 30, 2026, a federal judge sentenced Paradigm Peptides owner Matthew Kawa to 70 months after he pleaded guilty to selling unapproved drugs and illegal importation. According to CBS News, the company sold under a research-use disclaimer, and government tests found testosterone in products it sold as SARMs. Our United States peptide regulations page has more detail.

European Union and the UK

In the EU, a medicine must be authorised before it can be marketed, either EU-wide by the European Commission after review by the European Medicines Agency or by individual countries. As of October 2026, a peptide sold for injection without either kind of authorisation is an unauthorised medicine. Each member state enforces the rules through its own agency, so personal-import tolerance varies.

Ireland shows the scale. In March 2026, its Health Products Regulatory Authority (HPRA) reported detaining 763,027 dosage units of illegal medicines in 2025. GLP-1 products jumped from 1,582 units to 48,752. Most were drops or patches claiming to contain semaglutide or tirzepatide, and HPRA's tests found no semaglutide in the patches it sampled. In INTERPOL's Operation Pangea XVIII (March 2026), Ireland reported significant seizures of peptide vials. So did Australia and New Zealand.

Since Brexit, the UK regulates medicines through the MHRA under the Human Medicines Regulations 2012. On May 28, 2026, MHRA officers raided a site near Northampton and recovered about 12,000 doses of unlicensed weight-loss medicines, retatrutide among them. The agency called it its largest-ever seizure of such products. Our European Union peptide regulations page goes country by country.

Australia and New Zealand

As of October 2026, Australia regulates peptide products as therapeutic goods under the Therapeutic Goods Act 1989. Any that isn't on the Australian Register of Therapeutic Goods (ARTG) is unapproved. A June 2025 Medsafe paper notes that BPC-157 and TB-500 are prescription medicines in Australia.

On April 13, 2026, the TGA issued a safety alert that named BPC-157 and retatrutide among five example peptides. It said a "research use only" disclaimer doesn't change a product's regulatory status or permit importation. Unlabelled or code-only vials won't be released under the Personal Importation Scheme. Adverse events reported to the TGA included severe allergic reactions needing adrenaline and hospital care. Pharmacists have also been barred from compounding GLP-1 medicines since October 1, 2024.

New Zealand applies the Medicines Act 1981. Medsafe classified BPC-157 as a prescription medicine in May 2023 after people imported it for personal use. A notice dated December 17, 2025 widened that to BPC-157 and its analogues. It also added group entries for mitochondria-derived and myostatin modulator peptides, so new variants are caught automatically.

Medsafe's May 21, 2026 advisory says that without authorisation it is unlawful even to possess or procure a prescription medicine. It adds that "research purposes only" wording "has no legal effect." That possession rule is a real difference from the US, where the 2026 enforcement we found targeted sellers. Our Australia and New Zealand regulations page covers both countries in more depth.

Asia-Pacific

Singapore's Health Sciences Authority (HSA) warned on September 25, 2026 about injectable peptides sold online for weight loss and muscle gain. It named retatrutide and cagrilintide, said no regulator has approved them as medicines, and reported cases of anaphylaxis. HSA told consumers to treat "research use only" labels "as a warning sign" and says it monitors e-commerce sites for illegal listings.

Japan's health ministry (MHLW) lets travellers bring in up to a month's supply of a prescription drug for personal use without an Import Confirmation certificate. Larger amounts need one before departure. As of October 2026, the exemption for injectables covers only pre-filled syringes and self-injection kits, so in our reading a vial of peptide powder doesn't qualify.

In Thailand, INTERPOL reported that a raid on an aesthetic clinic seized more than 300 vials of semaglutide and tirzepatide meant for online customers.

Much of the gray-market supply starts in this region. Court filings showed Paradigm Peptides imported its products from China and India, according to CBS News. We didn't research Chinese or Indian export rules for this overview. Our Asia-Pacific peptide regulations page covers individual countries.

Canada

Health Canada's April 9, 2026 advisory says peptides are "generally regulated as prescription drugs" in Canada and that research-use labelling "does not make these products legal." Its list of seized examples runs from BPC-157 and TB-500 to SS-31 and retatrutide. Health Canada said it is working with the Canada Border Services Agency to stop shipments.

What to watch next

• Whether FDA proposes a rule or an interim policy for the six peptides its advisers backed, and what the second advisory meeting decides.
• Whether other regulators follow New Zealand in classifying whole peptide families rather than one compound at a time.
• How Australia's Poisons Standard schedules individual peptides. We didn't check those entries for this overview.
• Personal-import tolerance in individual EU countries, which we didn't verify this cycle.